Interobserver and intraobserver variability of RECIST assessment in ovarian cancer.


Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626

Informations de publication

Date de publication:
03 05 2022
Historique:
pubmed: 6 4 2022
medline: 6 5 2022
entrez: 5 4 2022
Statut: epublish

Résumé

Measurement of Response Evaluation Criteria In Solid Tumors (RECIST) relies on reproducible unidimensional tumor measurements. This study assessed intraobserver and interobserver variability of target lesion selection and measurement, according to RECIST version 1.1 in patients with ovarian cancer. Eight international radiologists independently viewed 47 images demonstrating malignant lesions in patients with ovarian cancer and selected and measured lesions according to RECIST V.1.1 criteria. Thirteen images were viewed twice. Interobserver variability of selection and measurement were calculated for all images. Intraobserver variability of selection and measurement were calculated for images viewed twice. Lesions were classified according to their anatomical site as pulmonary, hepatic, pelvic mass, peritoneal, lymph nodal, or other. Lesion selection variability was assessed by calculating the reproducibility rate. Lesion measurement variability was assessed with the intra-class correlation coefficient. From 47 images, 82 distinct lesions were identified. For lesion selection, the interobserver and intraobserver reproducibility rates were high, at 0.91 and 0.93, respectively. Interobserver selection reproducibility was highest (reproducibility rate 1) for pelvic mass and other lesions. Intraobserver selection reproducibility was highest (reproducibility rate 1) for pelvic mass, hepatic, nodal, and other lesions. Selection reproducibility was lowest for peritoneal lesions (interobserver reproducibility rate 0.76 and intraobserver reproducibility rate 0.69). For lesion measurement, the overall interobserver and intraobserver intraclass correlation coefficients showed very good concordance of 0.84 and 0.94, respectively. Interobserver intraclass correlation coefficient showed very good concordance for hepatic, pulmonary, peritoneal, and other lesions, and ranged from 0.84 to 0.97, but only moderate concordance for lymph node lesions (0.58). Intraobserver intraclass correlation coefficient showed very good concordance for all lesions, ranging from 0.82 to 0.99. In total, 85% of total measurement variability resulted from interobserver measurement difference. Our study showed that while selection and measurement concordance were high, there was significant interobserver and intraobserver variability. Most resulted from interobserver variability. Compared with other lesions, peritoneal lesions had the lowest selection reproducibility, and lymph node lesions had the lowest measurement concordance. These factors need consideration to improve response assessment, especially as progression free survival remains the most common endpoint in phase III trials.

Identifiants

pubmed: 35379690
pii: ijgc-2021-003319
doi: 10.1136/ijgc-2021-003319
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

656-661

Informations de copyright

© IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Michael Krasovitsky (M)

Medical Oncology, Prince of Wales Hospital and Royal Hospital for Women, Randwick, New South Wales, Australia.
Faculty of Medicine and Health, University of New South Wales, Sydney, New South Wales, Australia.

Yeh Chen Lee (YC)

Medical Oncology, Prince of Wales Hospital and Royal Hospital for Women, Randwick, New South Wales, Australia.
Faculty of Medicine and Health, University of New South Wales, Sydney, New South Wales, Australia.
NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia.

Hao-Wen Sim (HW)

Faculty of Medicine and Health, University of New South Wales, Sydney, New South Wales, Australia.
NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia.

Tanya Chawla (T)

Joint Department of Medical Imaging, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
University of Toronto, Toronto, Ontario, Canada.

Helen Moore (H)

Department of Radiology, Auckland City Hospital, Auckland, Hospital, New Zealand.

Daniel Moses (D)

Department of Radiology, Prince of Wales Hospital and Royal Hospital for Women, Randwick, New South Wales, Australia.

Luke Baker (L)

Westmead Hospital, Westmead, New South Wales, Australia.

Catherine Mandel (C)

Swinburne University of Technology, Hawthorn, Victoria, Australia.

Ania Kielar (A)

University of Toronto, Toronto, Ontario, Canada.
University of Ottawa, Ottawa, Ontario, Canada.

Angus Hartery (A)

Memorial University of Newfoundland, St John's, Newfoundland, Canada.

Martin O'Malley (M)

Joint Department of Medical Imaging, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
University of Toronto, Toronto, Ontario, Canada.

Michael Friedlander (M)

Medical Oncology, Prince of Wales Hospital and Royal Hospital for Women, Randwick, New South Wales, Australia.
Faculty of Medicine and Health, University of New South Wales, Sydney, New South Wales, Australia.

Amit M Oza (AM)

University of Toronto, Toronto, Ontario, Canada.
Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.

Lisa Wang (L)

University of Toronto, Toronto, Ontario, Canada.
Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.

Stephanie Lheureux (S)

University of Toronto, Toronto, Ontario, Canada.
Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.

Michelle Wilson (M)

Cancer and Blood, Auckland City Hospital, Auckland, New Zealand MiWilson@adhb.govt.nz.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH